Boskabady, MortezaBoskabady, Mohammad HosseinMansouri, FaribaShafei, Mohammad Naser2013-03-112013-03-112010-08Boskabady Morteza, Boskabady Mohammad Hossein, Mansouri Fariba, Shafei Mohammad Naser. Pharmacologic bronchodilation response to salbutamol in COPD patients. Indian Journal of Medical Sciences. 2010 Aug; 64(8) 363-372.http://imsear.searo.who.int/handle/123456789/145554Background: Airway hyperresponsiveness (AHR) is the most characteristic feature of asthma, which is reported in COPD patients and smokers. Increased airway responsiveness to ί-agonists is also demonstrated in asthmatics as well as smokers. However, there is no report regarding AHR to ί-agonist drugs in COPD patients. Therefore, in this study pharmacologic bronchodilation response to salbutamol in COPD patients was examined. Materials and Methods: The threshold concentrations of inhaled salbutamol required for a 20% change in forced expiratory flow in 1 sec (FEV 1 ) as PC 20 , or a 35% change in specific airway conductance (sGaw) as PC 35 was measured in 14 COPD patients and 14 normal subjects. Results: Airway responsiveness to salbutamol in COPD patients (PC 20 = 14.14 ± 1.62 and PC 35 = 9.70 ± 1.48 mg/l) was significantly lower than normal subjects (PC 20 = 224.57 ± 16.62 and PC 35 = 81.87 ± 8.16 mg/l, P < 0.001 for both cases). The values of FEV 1 and sGaw in COPD patients (56.43 ± 14.45 and 0.081 ± 0.120 respectively) were significantly lower than those of normal subjects (104.07 ± 5.72 and 0.194 ± 0.041 respectively), (P < 0.001 for FEV 1 and P < 0.005 for sGaw). There was a significant correlation between FEV 1 with PC 20 salbutamol (r = 0.862, P < 0.001). The correlations between PC 20 and PC 35 was also statistically significant (r = 0.862, P < 0.001). Conclusion: These results showed increased airway responsiveness of most COPD patients to salbutamol which was highly correlated to airway caliber.enAirway caliberairway responsivenessCOPDsalbutamolsmokerAdultAgedAirway Remodeling --drug effectsAirway Resistance --dug effectsAlbuterol --pharmacokineticsAlbuterol --pharmacologyAnti-Asthmatic Agents --pharmacologyAnti-Asthmatic Agents --therapeutic useAsthma --drug therapyAsthma --physiopathologyBronchi --drug effectsBronchi --pharmacologyBronchi --physiologyBronchial Hyperreactivity --pharmacologyBronchodilator Agents --pharmacokineticsBronchodilator Agents --pharmacologyPatientsPulmonary Disease, Chronic Obstructive --drug therapySmoking --adverse effectsSmoking --complicationsBronchial Hyperreactivity --physiopathologyArticle